China to Account for 16% of Global Pharma CDMOs in 2026

---

Researched by Industrial Info Resources (Sugar Land, Texas)--A key element of China's Pharmaceutical & Biotech Industry is set for major growth. China's share of the global market for contract development and manufacturing organizations (CDMO) already has grown significantly since 2016, and it is expected to expand further over the next five years.

From 2016 to 2020, the industry's CDMO market grew from 10.5 billion yuan (US$1.53 billion) in value to 31.7 billion yuan (US$4.62 billion), and the compound annual growth rate (CAGR) reached 32% over the same period, according to a study by Frost & Sullivan (San Antonio, Texas). From 2020 to 2025, its market size is expected to grow at an even faster rate, with a CAGR of 31.3%.

By 2025, China's pharmaceutical CDMO industry is expected to reach 123.5 billion yuan (US$18 billion) in value. By 2026, China will account for about 16% of the global CDMO market.

Industrial Info is tracking 27 CDMO projects across China, with a total investment value of US$4.35 billion. These projects are obviously concentrated in Shanghai and the Jiangsu, Zhejiang and Guangdong provinces in southern China. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of detailed project reports, and click here for a list of related plant profiles.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) platform helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 trillion (USD).